Project Information

More than 120 monoclonal antibodies are currently being developed and tested. They could theoretically be used for successful treatment of various illnesses like for example cancer or Alzheimer’s disease, however, therapy costs are extremely high and production capacities fall short when these products are launched to the market. Therefore, the EC decided to provide funding for the Integrated Project AIMs (Advanced Interactive Materials by Design), which focuses on the investigation of possibilities to improve production technologies for biotech pharmaceuticals on the example of monoclonal antibodies (MABs).

24 partner institutions from 12 European countries coordinated by Prof. Andrzej Górak from the University of Dortmund will be working on this topic for four years.